AbCellera Biologics Q4 2023 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $9.18M Beat $8.88M Estimate

2/20/24 4:26:02 PM ET

Pharmaceuticals and Biotechnology

Health Care

Get the next $ABCL alert in real time by email

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. The company reported quarterly sales of $9.18 million which beat the analyst consensus estimate of $8.88 million by 3.31 percent. This is a 57.40 percent decrease over sales of $21.55 million the same period last year.

Get the next $ABCL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABCL

Date	Price Target	Rating	Analyst
8/20/2024		Buy → Hold	The Benchmark Company
2/22/2024	$9.00	Hold → Buy	The Benchmark Company
12/5/2023	$6.00	Overweight	KeyBanc Capital Markets
11/6/2023		Buy → Hold	The Benchmark Company
10/13/2023	$20.00	Overweight	Piper Sandler
2/28/2023		Outperform	Cowen
12/15/2022	$30.00	Buy	Goldman
11/16/2022	$29.00	Buy	Truist

More analyst ratings

$ABCL
Leadership Updates

Live Leadership Updates

AbCellera Announces Resignation of Board Member
AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir
2/23/24 4:30:00 PM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care
DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer
TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev
6/13/23 7:59:57 AM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care
AbCellera Announces Changes to Its Board of Directors
AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d
12/7/21 9:00:00 AM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care

$ABCL
Press Releases

Fastest customizable press release news feed in the world

AbCellera to Present at Upcoming Investor Conferences in December and January
AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) Live audio webcasts of the presentation may be accessed through the link that will be posted on AbCellera's Investor Relations website. Replays of the webcast will be available through the same links following the presentations. About AbCellera Biologics Inc. AbCel
11/21/24 4:05:00 PM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
AbCellera (NASDAQ:ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas. AbCellera's presentation, which is available for viewing here, describes: Strategies to address key challenges in TCE development: CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor-cell killing and optimal cytokine release Molecules to enhance efficacy for solid tumor indications by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB Application of the platform to tw
11/7/24 10:05:00 AM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care
AbCellera Reports Q3 2024 Business Results
AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments." Q3 2024 Business Summary Expanded existing collaboration with E
11/4/24 4:05:00 PM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care

AbCellera Reports Q3 2024 Business Results
AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments." Q3 2024 Business Summary Expanded existing collaboration with E
11/4/24 4:05:00 PM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
AbCellera (NASDAQ:ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data
9/26/24 4:05:00 PM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care
AbCellera Reports Q2 2024 Business Results
AbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "This quarter, we made important progress on our internal pipeline and aim to submit applications for clinical trials for ABCL635 and ABCL575 in the second quarter of 2025. In parallel, we have focused preclinical work on our T-cell engager platform to four molecules for indications in oncology and autoimmunity," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Since our last earnings release, two of our partners have achieved notable milestones, including Abdera's IND clearance and Fast Tr
8/6/24 4:05:00 PM ET
$ABCL
Pharmaceuticals and Biotechnology
Health Care

AbCellera Biologics Q4 2023 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $9.18M Beat $8.88M Estimate

Chat with this insight

Recent Analyst Ratings for $ABCL

$ABCL SEC Filings

SEC Form 10-Q filed by AbCellera Biologics Inc.

AbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by AbCellera Biologics Inc.

$ABCL Leadership Updates

Live Leadership Updates

AbCellera Announces Resignation of Board Member

DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

AbCellera Announces Changes to Its Board of Directors

$ABCL Press Releases

Fastest customizable press release news feed in the world

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Reports Q3 2024 Business Results

$ABCL Financials

Live finance-specific insights

$ABCL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ABCL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ABCL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ABCL Large Ownership Changes

This live feed shows all institutional transactions in real time.

AbCellera Reports Q3 2024 Business Results

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Reports Q2 2024 Business Results

Chief Executive Officer Hansen Carl L. G. exercised 56,125 shares at a strike of $2.70, increasing direct ownership by 7% to 841,875 units (SEC Form 4)

Large owner Thermopylae Holdings Ltd. bought $739,977 worth of shares (283,516 units at $2.61), increasing direct ownership by 0.51% to 56,086,009 units (SEC Form 4)

Chief Operating Officer Lecault Veronique exercised 83,334 shares at a strike of $0.19, increasing direct ownership by 4% to 2,123,456 units (SEC Form 4)

Large owner Thermopylae Holdings Ltd. bought $739,977 worth of shares (283,516 units at $2.61), increasing direct ownership by 0.51% to 56,086,009 units (SEC Form 4)

Montalbano John S. bought $137,400 worth of shares (30,000 units at $4.58), increasing direct ownership by 54% to 86,000 units (SEC Form 4)

Hayden Michael R bought $98,200 worth of shares (20,000 units at $4.91) (SEC Form 4)

AbCellera Biologics downgraded by The Benchmark Company

AbCellera Biologics upgraded by The Benchmark Company with a new price target

KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target

Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

SEC Form SC 13G filed by AbCellera Biologics Inc.

SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

$ABCL Market Insights

Live Market Insights

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $5

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7

AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate

Recent Analyst Ratings for
$ABCL

$ABCL
SEC Filings

$ABCL
Leadership Updates

$ABCL
Press Releases

$ABCL
Financials

$ABCL
Insider Trading

$ABCL
Insider Purchases

$ABCL
Analyst Ratings

$ABCL
Large Ownership Changes

$ABCL
Market Insights